Select Page

Another great EpiVax article. Congratulations team!

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?

Anne S. De Groot,1,2 Leslie Cousens,2 Federico Mingozzi,3,4 and William Martin2

1Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA
2EpiVax, Inc., 146 Clifford Street, Providence, RI, USA
3Genethon, Evry, France
4University Pierre and Marie Curie, Paris, France

Received 12 July 2013; Accepted 17 October 2013
Academic Editor: Darren R. Flower

AS. De Groot, et al. “Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?,” Clinical and Developmental Immunology, vol. 2013, Article ID 493138, 6 pages, 2013. doi:10.1155/2013/493138. LINKED HERE, PDF HERE

“Clinical and Developmental Immunology” is an open access journal, meaning that the full-text of all published articles is made freely available on the journal’s website with no subscription or registration barriers – (EpiVax loves that!).

Potential IgG (and Tregitope) Mechanisms of Action. From left to right, IVIG has been demonstrated to affect the cells of the innate and adaptive immune system including NK cells, macrophages, B cells, T cells, dendritic cells and other antigen presenting cells.

Potential IgG (and Tregitope) Mechanisms of Action. From left to right, IVIG has been demonstrated to affect the cells of the innate and adaptive immune system including NK cells, macrophages, B cells, T cells, dendritic cells and other antigen presenting cells.
Illustration by: Genna De Groot